Skip to main content
Daniel Kuritzkes, MD, Infectious Disease, Boston, MA

DanielRobertKuritzkesMD

Infectious Disease • Boston, MA

Professor of Medicine, Brigham and Women's Hospital

Join to view full profile

Dr. Kuritzkes is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Kuritzkes' full profile

Already have an account?

  • Office

    75 Francis St
    Boston, MA 02115
    Phone+1 617-732-5500

Education & Training

  • Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical School
    Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 1989 - 1990
  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Internal Medicine, 1987 - 1989
  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Internal Medicine, 1983 - 1986
  • Harvard Medical School
    Harvard Medical SchoolClass of 1983

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1984 - 2025
  • CO State Medical License
    CO State Medical License 1990 - 2013
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Infectious Disease

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Post-Treatment Controllers Identified from 14 Clinical Studies  
    Elizabeth Connick, Michael C Sneller, Jonathan Z Li, Paul Volberding, Daniel R Kuritzkes, Robert T Schooley, David Margolis, Daniel Skiest, John W Mellors, Ronald Mits..., The Journal of Infectious Diseases
  • Targeted HIV Testing at Birth Supported by Low and Predictable Mother‐to‐Child Transmission Risk in Botswana  
    Daniel Kuritzkes, MD, Journal of the International AIDS Society

Authored Content

  • Hematopoietic Stem Cell Transplantation for HIV CureJanuary 2016

Press Mentions

  • Infections, Sewage and Mosquito-Borne Illness Outlast Hurricanes
    Infections, Sewage and Mosquito-Borne Illness Outlast HurricanesOctober 15th, 2024
  • Additional Human Cases of EEE and West Nile Virus Identified in Mass., Health Officials Say
    Additional Human Cases of EEE and West Nile Virus Identified in Mass., Health Officials SaySeptember 6th, 2024
  • Massachusetts' COVID Emergency Ends Thursday: What It Means for You
    Massachusetts' COVID Emergency Ends Thursday: What It Means for YouMay 8th, 2023
  • Join now to see all

Grant Support

  • Partners Healthcare Systems/Harvard Medical School/Boston Medical Center AIDS CtuNational Institute Of Allergy And Infectious Diseases2007–2012
  • AIDS Clinical Trials Group NetworkNational Institute Of Allergy And Infectious Diseases2011
  • HIV-1 Resistance To Chemokine Receptor AntagonistsNational Institute Of Allergy And Infectious Diseases2007–2011
  • AIDS Clinical Trials Group NetworkNational Institute Of Allergy And Infectious Diseases2010
  • V3 Loop Characterization By Ultradeep Sequencing During CCR5 Antagonist TherapyNational Institute Of Allergy And Infectious Diseases2009–2010
  • HIV-1 Therapeutics And Drug ResistanceNational Center For Research Resources2002–2010
  • A Phase IV Study Of Antiretroviral Therapy For Hiv-Infected AdultsNational Center For Research Resources2006
  • Fitness Of Enfuvirtide-(T-20)-Resistant HIV-1National Institute Of Allergy And Infectious Diseases2003–2006
  • AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases2003–2006
  • HIV-1 Resistance To Nucleoside AnaloguesNational Institute Of Allergy And Infectious Diseases2002–2004
  • Viracept And Sustiva For Treatment Of HIV-1National Center For Research Resources2000–2002
  • Phase I Trial Of T-1249 In HIV Infected AdultsNational Center For Research Resources2000–2002
  • Actg370 Lamivudine VS Delavirdine In 3TC Experienced SubjectsNational Center For Research Resources1998–2002
  • Actg364 Efficacy Of Nelfinavir AND/OR DMP 266 With Nucleoside AnalogsNational Center For Research Resources1998–2002
  • HIV-1 Resistance To Nucleoside AnaloguesNational Institute Of Allergy And Infectious Diseases2001
  • HIV-1 Therapeutics And Drug ResistanceNational Center For Research Resources2001
  • PNU 140690 Dose Escalation--Eval Tolerance Pharmacokinetics Eff In HIVNational Center For Research Resources1999–2000
  • HIV-1 Dual Resistance To AZT And 3TCNational Institute Of Allergy And Infectious Diseases1998–2000
  • Pharmacokinetics Of Indinavir SulfateNational Center For Research Resources1998–1999
  • Hiv-1-Specific Ctls In Perinatally Exposed ChildrenNational Institute Of Allergy And Infectious Diseases1993–1997
  • ACTG 251--Thalidomide Treatment For Oral/Esophageal Aphthous UlcersNational Center For Research Resources1996
  • ACTG 242--Amytryptilene/Mexiletine For HIV NeuropathyNational Center For Research Resources1996
  • Thalidomide Treatment For Oral/Esophageal Aphthous Ulcers + HIV ViremiaNational Center For Research Resources1995
  • Evaluation Of Antiviral Effects Of RibozymesNational Institute Of Allergy And Infectious Diseases1994–1995
  • HIV Epitopes Recognized By Cytotoxic T LymphocytesNational Institute Of Allergy And Infectious Diseases1990–1993
  • Functional Domains Of HTLV Envelope ProteinsNational Center For Research Resources1991
  • HIV Epitopes Recognized By Cytotoxic T LymphocytesNational Institute Of Allergy And Infectious Diseases1989–1990

Dr. Daniel Kuritzkes, Dr. Daniel Kuritzkes, MD, Dr. D Kuritzkes, Dr. Daniel Robert Kuritzkes